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Abstract
Background: Recombinant antibody fragments have a wide range of applications in research, diagnostics and
therapy. For many of these, small fragments like single chain fragment variables (scFv) function well and can be
produced inexpensively in bacterial expression systems. Although Escherichia coli K-12 production systems are
convenient, yields of different fragments, even those produced from codon-optimized expression systems, vary
significantly. Where yields are inadequate, alternative production systems are needed. Pseudomonas putida strain
KT2440 is a versatile biosafety strain known for good expression of heterologous genes, so we have explored its
utility as a cell factory for production of scFvs.
Results: We have generated new broad host range scFv expression constructs and assessed their production in
the Pseudomonas putida KT2440 host. Two scFvs bind either to human C-reactive protein or to mucin1, proteins of
significant medical diagnostic and therapeutic interest, whereas a third is a model anti-lysozyme scFv. The KT2440
antibody expression systems produce scFvs targeted to the periplasmic space that were processed precisely and
were easily recovered and purified by single-step or tandem affinity chromatography. The influence of promoter
system, codon optimization for P. putida, and medium on scFv yield was examined. Yields of up to 3.5 mg/l of
pure, soluble, active scFv fragments were obtained from shake flask cultures of constructs based on the original
codon usage and expressed from the Ptac expression system, yields that were 2.5-4 times higher than those from
equivalent cultures of an E. coli K-12 expression host.
Conclusions: Pseudomonas putida KT2440 is a good cell factory for the production of scFvs, and the broad host
range constructs we have produced allow yield assessment in a number of different expression hosts when yields
in one initially selected are insufficient. High cell density cultivation and further optimization and refinement of the
KT2440 cell factory will achieve additional increases in the yields of scFvs.
Background
Recombinant antibodies and antibody fragments are
indispensable tools for research, diagnostics and therapy
[1-5]. Complete and natively glycolsylated antibodies,
like IgGs, needed for therapeutic purposes must thus far
be produced in mammalian cells. However, although
yields from mammalian cells tend to be good, produc-
tion times and costs are high [6]. However, for many
non-therapeutic applications, and also some therapeutic
applications for which effector functions are not
necessary, antibody modules, such as single chain frag-
ment variable (scFv) and fragment antigen binding (Fab)
are sufficient [7,8]. Because of their lower costs and fas-
ter production cycles, microbial systems are more
attractive than mammalian cell systems for the produc-
tion of antibody fragments. The folding and export of
scFvs in Gram-negative systems is usually more efficient
than that of Fab fragments [9]. One problem with pro-
karyotic production systems is that expression levels of
fragments of different antibodies tend to differ markedly
[10,11] and, in many instances, only synthetic, codon-
usage adapted, genes provide significant yields. The
availability of a core suite of distinct efficient host-broad
host range expression cloning vector systems, differing
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nation of optimal production systems for different
proteins.
Pseudomonas putida strain KT2440 is a metabolically
versatile soil bacterium with considerable potential in a
broad range of diverse industrial and environmental
applications [12]. Its certification as a biosafety strain
[13,14], its ability to express a broad spectrum of foreign
proteins at high levels and the availability of powerful
customized tools for genetic analysis and manipulation
[15], make KT2440 an important prokaryotic cell fac-
tory. These features suggest that it might be a useful
production system for antibody fragments.
In this study, we have assessed the potential of
KT2440 for the soluble production of different recombi-
nant scFvs namely, the model murine anti-hen egg-
white lysozyme scFv, D1.3 [11,16-19], and two phage
display-selected human scFvs: TOB5-D4 [[11], Al-Halabi
et al. in preparation], directed against C-reactive protein
(CRP) [20], an inflammation indicator in human blood,
and HT186-D11 [21], directed against mucin1 (MUC1),
a diagnostic marker and potential therapeutic target of
cancer [22,23].
Results and Discussion
Expression plasmids and synthetic genes
The key features of the antibody expression plasmids
constructed in this study are shown in Table 1. They
were generated using new synthetic RK2 broad host
range plasmid-based chassis developed by the group of
Victor de Lorenzo (in preparation) carrying either the
inducible Ptac [13,24] or TOL plasmid xyl operon Pm
[25,26] promoters. We further modified the chassis by
equipping it with the G10L ribosome binding site (RBS)
with epsilon enhancer [27] and the Erwinia carotovora
pelB leader sequence [28] to effect the export of
expressed polypeptides to the periplasm. The scFv for-
mat consists of variable regions of the antibody heavy
and light chains (VH and VL, respectively), joined by a
15-25 amino acid linker [29]. Polynucleotide sequences
encoding Myc-HIS6-Strep-Tag
® II or HIS6-Myc-Strep-
Tag
® II affinity tags were placed downstream of the
VH-linker-VL coding sequences (Table 1) to facilitate
purification and detection of the scFvs in western blots
and enzyme-linked immunosorbent assays (ELISA). In
addition, synthetic scFv genes were generated to assess
the influence of codon usage adaptation on expression
levels in P. putida (Table 1). The original scFv gene
constructs were expressed from the Ptac promoter,
whereas the synthetic gene constructs were expressed
from either Ptac or Pm promoters (Table 1). Although
synthetic codon usage adapted gene constructs of
TOB5-D4 (anti-CRP) and HT186-D11 (anti-mucin1)
scFvs were readily generated, for unknown reasons the
equivalent version of D1.3 (anti-lysozyme) scFv could
not be synthezised by the commercial supplier. For gen-
eration of the native sequence constructs, the RBS and
Strep-tag
® II were added using primer overhangs.
Affinity isolation of scFvs
Different combinations of cell lysis and affinity purifica-
tion strategies were tested in order to determine a rapid,
simple isolation/purification protocol. Purification of
hexahistidine-tagged scFvs from clarified whole cell
extracts by immobilized metal ion affinity chromatogra-
phy (IMAC) resulted in a protein mixture containing
three major species between 30-50 kDa, of which the
mid band was confirmed by N-terminal sequencing to
be the scFv. The addition of a second affinity chromato-
graphy on Strep-Tactin Superflow in series (tandem)
resulted in scFv fragments of high purity with no visible
background in sensitively Coomassie Blue-stained SDS-
PAGE (data not shown). Single step purification on
Strep-Tactin Superflow resin in gravity flow columns,
however, proved sufficient for most purposes, including
yield determination. This single-step protocol yielded
scFv fragments with a purity of ~95%. Incubation of the
purified fragments for 16-24 h on ice, followed by at
least one freeze thaw cycle in elution buffer, did not
cause significant degradation of the scFvs (Figure 1).
Lysis of cells by sonication or use of the bacterial pro-
tein extraction reagent (B-Per, Thermo fisher scientific),
Table 1 Properties of the RK2-based broad-host range plasmid constructs with the Ptac/lacIq (pSEVAlac) or Pm/xylS
(pSEVAxyl) promoter/regulator gene systems used in this study
Construct scFv specificity Promoter Affinity-tags codon optimization
1 %G C
2
pSEVAlacD1.3n hen egg-white lysozyme Ptac HIS6/Myc/Strep-tag
® II _ 52,3
pSEVAlacTOB5-D4n human CRP Ptac Myc/HIS6/Strep-tag
® II _ 55,0
pSEVAlacTOB5-D4s human CRP Ptac Myc/HIS6/Strep-tag
® II Jcat/Eurofins MWG Operon 68,3
pSEVAxylTOB5-D4s human CRP Pm Myc/HIS6/Strep-tag
® II Jcat/Eurofins MWG Operon 68,3
pSEVAlacHT186-D11n human mucin1 Ptac HIS6/Myc/Strep-tag
® II _ 57,8
pSEVAlacHT186-D11s human mucin1 Ptac HIS6/Myc/Strep-tag
® II GeneOptimizer
®/GENEART 67,6
pSEVAxylHT186-D11s human mucin1 Pm HIS6/Myc/Strep-tag
® II GeneOptimizer
®/GENEART 67,6
1Synthetic scFv determinants with optimized codon usage: - indicates the original scFv sequence, Jcat/Eurofins MWG Operon and GeneOptimizer
®/GENEART
indicates a codon adaptation tool and a supplier;
2 %GC content of the scFv coding sequence.
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perhaps not surprising, given that the scFvs are targeted
to the periplasmic space. Moreover, purification of selec-
tively released periplasmic proteins (see below) by single
step Strep-Tactin Superflow chromatography resulted in
ap u r i t yc o m p a r a b l et ot h o s eo b t a i n e db yt h et a n d e m
strategy.
scFv yield optimization
Induction
Two transcriptional expression systems based on the Ptac
and Pm promoters, that are widely used to express hetero-
logous genes, were assessed for their efficacy in scFv
production by KT2440 in otherwise identical RK2 plas-
mid-based expression constructs (Table 1). In the case of
the TOB5-D4s and HT186-D11s scFvs, yields from the
Ptac promoter constructs were more than twice those
from the Pm promoter constructs. Optimal yield condi-
tions determined for Ptac constructs were 3 h induction
by 1 mM IPTG at 30°C in LB-medium, which gave yields
of 1.5 mg/l for the D1.3 scFv, 2.9 mg/l for the anti-CRP
scFv, and 3.6 mg/l for the HT186-D11 scFv (Figure 2;
yield means of 3-6 individual expression experiments
involving 100 ml cultures agitated at 180 rpm, and
isolation by single step affinity purification on 1 ml Strep-
Tactin Superflow gravity columns). The influence of med-
ium composition on yield was also assessed and it was
found that yields decreased in the order: Terrific Broth
(TB) > LB > M9 (15 mM succinate) > R2A (Figure 3),
indicating that enriched, buffered media favour scFv pro-
duction and that medium optimization has considerable
potential for yield enhancement.
Codon usage optimization
KT2440 is an expression host with a high average GC
content (~61.5%) and a codon usage preference distinct
from those of the scFv determinants used in this study
[14]. To assess to which extent adaptation of the scFv
codons to those preferred by KT2440 could influence
scFv yields, synthetic scFv determinants composed of
the preferred codons were designed in silico, synthesized
and tested in the expression systems. Although synthetic
versions of the TOB5-D4 (anti-CRP) and HT186-D11
(anti-MUC1) scFv sequences were made, it was not
possible to obtain a synthetic version of the D1.3 (anti-
lysozyme) scFv (Table 1). For the two former scFvs, it
was found that the yields - 2.4 mg/l for TOB5-D4s
(anti-CRP) and 2.1 mg/l for HT186-D11s (anti-MUC1)
(Figure 2) - were lower than those from the original
constructs, so in these cases, codon usage optimization
Figure 1 Purity of single-step affinity-purified scFvs from
KT2440. Proteins were isolated, affinity purified, incubated and
subjected to freeze:thaw cycles to assess their stability in elution
buffer, as described above and run on a 12.5% SDS polyacrylamide
gel. M = PAGE Ruler unstained protein molecular weight marker
(Fermentas); 1, D1.3; 2, TOB5-D4 (anti-CRP), 3, HT186-D11 (anti-
MUC1).
Figure 2 Yields of soluble scFvs from KT2440 constructs.M e a n
values and standard deviations are given of yields from single-step
purified soluble scFvs obtained from 3-6 independent expression
and purification experiments.
Figure 3 Effect of different culture media on HT186-D11
production. SDS-PAGE of single step purified scFvs from
periplasmic extractions of P. putida KT2440 cultures expressing scFvs
from construct HT186-D11n on different media.
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ability of KT2440 to efficiently express a broad range of
foreign genes, or limitation of higher levels of expression
otherwise attainable due to the higher than normal (for
KT2440) GC contents of the synthetic genes (Table 1),
or sub-optimal mRNA secondary structures created by
the changes [30].
The key question arising from these results is how the
scFv yields obtained compare with those obtainable
from existing expression systems. Unfortunately, perti-
nent information could not be found in the literature,
and values that are available are not usable due to dif-
ferences in antibody and/or experimental procedures
followed. To obtain relevant information on this issue,
we introduced the broad range constructs into the
Escherichia coli expression strain BL21 (DE3). Yields of
the TOB5-D4n and HT186-D11n scFvs from E. coli
were 2.5 to 4-fold lower than those from KT2440, and,
as might be predicted, even lower in the case of the
high GC synthetic genes (data not shown). Literature
yields in E. coli for an anti-CRP scFv antibody of 0.55
mg/l [31] and the D1.3 scFv antibody of 0.29 mg/l [10]
lie within the same low range.
Periplasmic export
All genetic constructs were designed to create precise
amino-terminal translational fusions of the scFv-coding
sequences with the E. carotovora pelB signal sequence to
target the scFvs for secretion by the Sec pathway. For
assessment of the efficiency of processing of the scFv
fragments produced in KT2440, and their translocation
to the periplasm, periplasmic fractions were isolated.
This procedure generally gave scFv yields in the same
range as, though with greater variability than, those
obtained by whole cell lysis. To ascertain whether the
increased variation in yield is due to incomplete release
of periplasmic proteins during the isolation procedure or
incomplete translocation to the periplasm, perhaps
resulting from overloading of the secretion apparatus,
Sec-mediated proteolytic cleavage of the pelB leader
sequences of the scFvs was analyzed by electrophoretic
separation followed by western blot detection of the
C-terminal Strep-tag
® II (Figure 4A). As expected, only
fully processed scFvs were detected in periplasmic pre-
parations, indicating that periplasmic scFvs are comple-
tely processed. In the case of proteins extracted from
w h o l ec e l l s ,o n l yf u l l yp r o c essed mature anti-CRPs were
detectable, although small amounts of unprocessed
HT186-D11n and HT186-D11s scFvs were identified
(Figure 4A, compare Figure 1), indicating that at the
moment of sampling small amounts of untransported
protein were still in the cytoplasm. The ratio of pro-
cessed:unprocessed polypeptide did not seem to correlate
with expression levels, since unprocessed protein was
also observed in cells carrying the lower expressing
HT186-D11s construct. More likely is the possibility that
the VH-coding amino acid sequence affects the second-
ary structure around the cleavage junction and negatively
impacts on the efficiency of processing. The variable
yields in periplasmic extracts probably reflect incomplete
disruption of the outer membrane by the procedure we
used, but might also result from partial non-specific leak-
age of periplasmic proteins to the medium, a phenom-
enon previously observed for antibody fragments
exported by means of the PelB leader peptide in E. coli
[32]. It should, nevertheless, be emphasized that this pro-
cedure for selective isolation of periplasmic proteins has
the major advantage of yielding active, soluble antibody
fragments uncontaminated by cytoplasmic proteins.
The signal peptide cleavage sites of the recombinant
scFvs were predicted by means of the in silico tool
Figure 4 Periplasmic export of scFvs and signal peptide
cleavage. A.) Western-blot of purified antibodies extracted from
whole cells (WCE) and periplasmic preparations (PPP) and
chromogenic detection of the Strep-tag
® II at the C-terminus.
A minor fraction of incomplete N-terminal processing (cleavage of
the 22 amino acid pelB-leader sequence) is visible only in the case
of HT186-D11 whole cell extracts (arrows). B.) N-terminal sequencing
by Edman degradation confirmed the predicted cleavage sites
following the A-M-A motif. X, amino acid position with ambiguous
identification.
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23, directly after the A-M-A motif, which is also the
preferred sequence motif (A-X-A) for interaction with
signal peptidase I [34], and experimentally confirmed by
N-terminal sequencing of isolated antibody (Figure 4B).
Other sites of cleavage were not detected, which indi-
cates that the KT2440 LepB peptidase (PP_1432), which
shares 39% amino acid identity and 52% similarity with
the E. coli K-12 peptidase, precisely recognizes and
cleaves the PelB processing site.
Antibody activity
In order to assess whether the extracted periplasmic
scFv polypeptides were correctly folded and had
acquired correct binding activity, the binding of the
TOB5-D4 and HT186-D11 antibodies to their cognate
antigens were measured by ELISA assays using plates
coated with 100 ng per well of either CRP antigen (Bios-
Pacific, Emeryville, USA), MUC1 32 aa peptide with a
C-terminal cysteine (APDTRPAPGSTAPPAHGVT-
SAPDTRPAPGSTA-C) [21], or bovine serum albumin
(BSA; controls). A primary mice anti-Myc-tag IgG, com-
bined with a secondary Fab-specific goat anti-mice IgG
horseradish peroxidase (HRP) conjugate were used for
detection of bound antibody, as previously described
[35]. As can be seen in Figure 5, high specific antigen
binding was observed for both recombinant scFvs, with
significant signals recorded till antibody concentrations
of 10 nM, which corresponds to dilutions of 1:256, for
an antibody having an initial concentration of 2.5 μM.
Recombinant anti-CRP antibody preparations obtained
from both whole cells and periplasmic extracts had
similar binding activities (data not shown), which is con-
sistent with the findings shown in Figure 4A and the
correct folding of periplasmic antibody.
Conclusions
We have presented here an assessment of the potential of
Pseudomonas putida KT2440 as a cell factory for the
production of soluble recombinant antibody fragments
that bind to antigens of high interest for diagnostics and
therapy. With the described construct design, good yields
of soluble, active scFvs are obtained through simple
extraction of periplasmic polypeptides and single step
affinity purification. These yields considerably exceeded
those obtained from equivalent constructs in E. coli K-12,
so KT2440 would seem to be a promising cell factory for
recombinant antibody fragment production. It is likely
that high density fed-batch cultivation of KT2440 [36],
which are typically characterized by cell densities of up to
more than 100 g/l, will allow achievement of much
higher yields by this host. A common means of optimiz-
ing expression levels of recombinant proteins is the use
of synthetic genes with host-optimized codon usage. In
our study, this approach did not achieve increased
expression, possibly due to the expression versatility of
this host for foreign genes. However, the possibility that a
less rigorous adaptation that maintains the P. putida
KT2440 natural % G+C value might give better expres-
sion would seem worth exploring in future, especially in
conjunction with other optimization efforts involving
exploration of media and cultivation conditions as well as
genetic engineering and genome streamlining
approaches. The broad host range feature of the con-
structs presented here will of course allow their testing in
other host systems and potential discovery of even more
powerful cell factories for antibody production.
Methods
Vector construction
Expression construct pSEVAlacTOB5-D4n was
generated by amplification of the scFv sequence from
antibody expression vector pOE101-TOB5-D4 [[11], Al-
Halabi et al. in preparation], using primers A (fw 5’-
GCGAATTCTTAACTTTAAGAAGGAGATATATCC
ATG A AATACCTATTGCCTACGGC-3’)a n dB( r e v
5’-GCTCTAGA TTACTTTTTCGAACTGCGGGTGGC
TCCA ATGATGATGGTGATGATGGGATAGATCT
Figure 5 Specific binding activities of the scFvs produced in
KT2440. The binding activities of the scFvs to cognate antigens
was measured by ELISA. The scFv concentration detection limits
were ~10 nM. Absorbance was measured at 450 nm and corrected
for absorbance at 620 nm.
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Sm-lac (pSEVA424). Vector pSEVAlacHT186-D11n was
generated amplifying HT186-D11 from phage display
vector pHAL14-HT186-D11 [11,21] using primers A
and C (5’-GCTCTAGA TTACTTTTCGAACTGCGGG
TGCGACCATGCGGCCCCATTCAGATCCTCTTCTG
AGATG-3’), and cloning via EcoRI and XbaI into
pSEVA-RK2-Sm-lac. Plasmid pSEVAlacD1.3n was con-
structed using the same primers and restriction sites for
the amplification product of pHAL14-D1.3 [11].
Sequences for ribosome binding sites [27], restriction
sites and the Strep-tag
® II [37] were added with the cor-
responding primer overlaps.
Vector pSEVAlacTOB5-D4s and pSEVAxylTOB5-D4s
were generated using an in silico-designed synthetic con-
struct incorporating the RBS and Strep-tag
® II. The
sequence was codon-usage adapted to that of P. putida
KT2440, using Jcat [38], and synthesized by Eurofins
MWG (Ebersberg, Germany). The construct was cloned
into pSEVA-RK2-Sm-lac and pSEVA-RK2-Sm-XylPm via
MfeI/EcoRI and XbaI. A synthetic construct was also gen-
erated from HT186-D11, codon usage adapted to P.
putida, and synthesized by GENEART (Regensburg, Ger-
many). Cloning in pSEVA-RK2-Sm-lac and pSEVA-RK2-
Sm-XylPm via EcoRI/HindIII resulted in pSEVA-
lacHT186-D11s and pSEVAxylHT186-D11s respectively.
All constructs contained the 66 bp Erwinia carotovora
pelB-leader sequence for periplasmic export and are sum-
marized in Table 1. E. coli strain DH5a, chemicals and
enzymes for PCR and cloning were purchased from Fer-
mentas (St. Leon-Rot, Germany) and New England Biolabs
(Ipswich, MA, USA). Integrity of the constructs was veri-
fied by sequencing the synthetic construct prior to cloning,
and restriction digestion after cloning. Native sequences
were amplified from sequence validated templates [11,21],
using high fidelity proof-reading polymerase (Phusion™)
and confirmed by restriction digestion after cloning.
Transformation of Pseudomonas putida KT2440
Competent cells were prepared using buffer containing
300 mM sucrose as described before [39]. 30 ng of plasmid
constructs were used to transform 40 μlo fc o m p e t e n tP.
putida KT2440 (DSM 6125) cells by electroporation,
which was carried out in prechilled 2 mm cuvettes using a
Gene Pulser II with pulse controller plus and capacitance
extender plus (Bio-Rad, Hempel Hempstead, UK). Cell:
DNA mixes were pulsed at 2.5 kV, 25 μF and 200-500Ω
resistance, and subsequently plated on selection medium
containing 100 μg/ml of streptomycin and spectinomycin.
Production of scFvs with Pseudomonas putida KT2440
An 50 ml overnight liquid culture of the P. putida
KT2440 clone freshly transformed with the respective
construct (Table 1) was used to inoculate the production
culture 1:100. Production test-cultures were grown in
200 ml cultures at 150 rpm at RT, 30°C and 37°C. Luria
Bertani (LB) (5 g/l yeast extract, 10 g/l tryptone, 10 g/l
NaCl), rich Luria Bertani Broth (10 g/l yeast extract,
10 g/l tryptone, 10 g/l NaCl), M9 containing 15 mM
succinate, TB, and R2A [40,41] containing 50 μg/ml
streptomycin were used in 500 ml baffled Erlenmeyer
flasks. In the mid logarithmic phase (at OD595 of ~0.5-
0.6), production was induced by addition of isopropyl-ß-
D-thiogalactopyranoside (I P T G )a tc o n c e n t r a t i o n s
ranging between 100 μMa n d1m M ,o r1 5m M
3-methylbenzoate, for pSEVAxyl-TOB5-D4s and pSE-
VAxyl-HT186-D11s. Final yields reported in Figure 2 are
from lysis of cells cultured in 100 ml LB at 180 rpm and
30°C. The cells were harvested by centrifugation.
Production of scFvs in E. coli
To compare yields of recombinant antibody fragments
from P. putida KT2440 with those from E. coli K-12, we
introduced the pSEVAlacTOB5-D4 and pSEVA-
lacHT186-D11 constructs containing the tac promoter
for expression into E. coli strain BL21 (lDE3) (Strata-
gene). K-12 and KT2440 constructs were cultured at RT
for HT186-D11n and 30°C for TOB5-D4n with other
parameters being as described for KT2440, which in
initial experiments also gave the best antibody yields in
E. coli.
Periplasmic export and signal peptide cleavage
To obtain periplasmic extracts, harvested cells were
resuspended in PE buffer (20% (w/v) sucrose, 50 mM
Tris, 1 mM EDTA, pH 8), incubated for 30 min on ice
with brief vortexing every 5 minutes, and centrifuged at
20,000 rcf for 30 min.
Completeness of signal peptide cleavage was assessed
by electrophoresis of antibody fragments on 12.5% SDS-
PAGE, semi-dry transfer to PVDF membranes (Peqlab),
and anti-Strep-tag detection using Strep-Tactin alkaline
phosphatase (AP) conjugate (IBA, Göttingen, Germany)
and chromogenic BCIP (5-Bromo-4-Chloro-3’-Indoly-
phosphate p-Toluidine Salt), NBT (Nitro-Blue Tetrazo-
lium Chloride) detection (AP Blue Membrane Substrate
Solution, Sigma). The cleavage position was determined
by N-terminal sequencing by Edman degradation and
compared to the in silico predicted sites obtained with
the Predisi tool [33].
Affinity purification of antibody fragments
The proteins were obtained by whole cell lysis by soni-
cation in sonication buffer (50 mM Tris, 100 mM NaCl,
5 mM MgCl2, 0,05% (v/v) Triton X-100, pH 8,0), bacter-
ial protein extraction reagent B-Per (Thermo Fischer
scientific) according to the manufacturer’si n s t r u c t i o n s ,
sonication in B-Per or by periplasmic extraction (see
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at 15,000 rcf to obtain cell-free extracts which, like peri-
plasmic preparations were applied directly to affinity
chromatography columns.
We used IMAC on Ni-TED (Machery-Nagel), for HIS-
tag-based affinity purification, or Strep-Tactin Superflow
(IBA) columns for Strep-tag
® II-based affinity purification,
or both in sequence. The washing and elution procedures
were carried out according to the manufacturers’ recom-
mendations. Protein concentrations of purified scFv solu-
tions were determined by the method by Gill and van
Hippel [42], using the individually calculated molar extinc-
tion coefficients for the processed amino acid sequences
without signal peptides (Protein Calculator v3.3, http://
www.scripps.edu/~cdputnam/protcalc.html), and the UV
absorbance at 280 nm (protein) and 260 nm (as control
for possible nucleic acid contamination), determined with
the NanoDrop
® ND-1000 spectrophotometer (Peqlab) or
lab spectrometer (Eppendorf).
Antigen binding ELISA
The antigens, in PBS, were used to coat wells of 96-well
microtitre plates (Maxisorp, Nunc). After coating over-
night at 4°C, the wells were washed three times with
PBST, and blocked with 2% (w/v) skim milk powder in
PBST (2% M-PBST) for 1.5 h at room temperature, fol-
lowed by three washes with PBST. For the ELISA, solu-
ble scFvs were diluted in 100 μl2 %M - P B S Ta n d
incubated in the antigen-coated plates for 1.5 h at room
temperature, followed by three PBST washes. Bound
scFvs were detected with the murine mAb (9E10,
Sigma), which recognises the C-terminal c-myc tag, and
a goat anti-mouse serum, conjugated with horseradish
peroxidase (HRP) (Sigma; 1:10,000). For visualisation the
chromogenic substrate 3,3’,5,5’-tetramethylbenzidine
(TMB) was added. The staining reaction was stopped by
addition of 100 μl 1 N sulphuric acid and absorbance at
450 nm and 620 nm was measured using a SUNRISE™
microtitre plate reader (Tecan, Crailsheim, Germany).
Abbreviations used
aa: amino acid; AP: alkaline phosphatase; RBS: ribosome binding site; CRP:
human C-reactive protein; EDTA: ethylenediaminetetraacetic acid; ELISA:
enzyme-linked immunosorbent assay; Fab: fragment antigen binding; HRP:
horseradish peroxidase; IgG: immunglobulin G; IMAC: immobilized metal ion
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